<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05612438</url>
  </required_header>
  <id_info>
    <org_study_id>P12204</org_study_id>
    <nct_id>NCT05612438</nct_id>
  </id_info>
  <brief_title>RADIX 2 RENAL STENT Post-Market Retrospective Study</brief_title>
  <acronym>RADIX 2</acronym>
  <official_title>RADIX 2 RENAL ARTERY STENT Evaluation of Safety and Performance in Everyday Clinical Practice: Post-Market Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CID S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CID S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Carbostent™ Radix 2 stent is a CE marked balloon expandable bare metal stent for the&#xD;
      treatment of renal artery stenosis.&#xD;
&#xD;
      The aim of this post-market retrospective study protocol P12204, is to collect clinical data&#xD;
      on patients treated with the RADIX 2 stent in routine clinical practice.&#xD;
&#xD;
      In order to obtain long-term follow-up data, the data collection will be limited to patients&#xD;
      that have been treated with the Radix 2 stent at least 12 months prior to the study start.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this post-market study is collect retrospective clinical data on the&#xD;
      implantable medical device Radix 2 stent in an unselected population treated in the current&#xD;
      clinical practice. Data will be collected via medical chart review in anonymous form.&#xD;
&#xD;
      Radix2 is a bare metal balloon expandable stent with a progressive multicellular design for&#xD;
      treatment of renal artery stenosis. The stent is stent coated with i-Carbofilm™ to accelerate&#xD;
      the rate of endothelization and strut coverage.&#xD;
&#xD;
      The product is CE marked and commercially available since July 2010. Additional technical&#xD;
      information on RADIX2 is available online:&#xD;
      http://www.alvimedica.com/Product/15/bms-b-e-radix2&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 3, 2023</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major renal events</measure>
    <time_frame>30 days</time_frame>
    <description>Major renal events at 30 days - composite of:&#xD;
death from renal causes, related to study device or procedure; embolic events related to study device or procedure, resulting in kidney damage; acute kidney injury Stage 3 (AKIN criteria); ipsilateral nephrectomy, related to the study device or procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute device success</measure>
    <time_frame>24 hours</time_frame>
    <description>Acute Device Success, defined as the successful delivery of the assigned device(s) to the designated target location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>24 hours</time_frame>
    <description>Technical Success, defined as the ability to implant the stent with a residual angiographic stenosis no greater than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Stent Restenosis</measure>
    <time_frame>12 months</time_frame>
    <description>Restenosis of Radix2 stent, requiring repeat revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Systolic and diastolic arterial blood pressure changes during follow-up</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Renal Artery Stenosis</condition>
  <condition>Renal Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RADIX 2 Stent</intervention_name>
    <description>RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis &gt; 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected with occlusive lesions of the native renal artery disease treated with&#xD;
        the study stent, these patients are generally affected by cardiovascular comorbidities with&#xD;
        a high incidence of mortality or in the terminal phase of the disease or in advanced age&#xD;
        and in serious health conditions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The study will be conducted in the &quot;real world&quot; population, according to the following&#xD;
        criteria.&#xD;
&#xD;
        Selection criteria:&#xD;
&#xD;
          -  Patient has been implanted with at least one study stent (Radix2) according to the&#xD;
             indications described in the IFU.&#xD;
&#xD;
          -  Study Device Implanted is at least12 months prior to the starting date of the&#xD;
             retrospective anonymous data collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated less than 12 months prior to study start&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Franco Vallana, MD</last_name>
    <phone>+39 0161 18261</phone>
    <email>franco.vallana@alvimedica.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Tocchi, MD</last_name>
    <email>m.tocchi@meditrial.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Pietro Montorsi, MD</last_name>
      <email>invasiva1@cardiologicomonzino.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.alvimedica.com/</url>
    <description>Manufacturer website</description>
  </link>
  <link>
    <url>https://meditrial.net/</url>
    <description>Clinical Research Organization</description>
  </link>
  <reference>
    <citation>Zeller T, Rastan A, Kliem M, Schwarzwalder U, Frank U, Burgelin K, Schwarz T, Amantea P, Muller C, Neumann FJ. Impact of carbon coating on the restenosis rate after stenting of atherosclerotic renal artery stenosis. J Endovasc Ther. 2005 Oct;12(5):605-11. doi: 10.1583/05-1599MR.1.</citation>
    <PMID>16212462</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 4, 2022</last_update_submitted>
  <last_update_submitted_qc>November 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

